愛愛醫(yī)推薦原文閱讀：
　　A quantitative, molecular **ysis of lymph nodes in patients deemed colorectal cancer-free was found to be an effective predictor of recurrence, according to a study from researchers at the Kimmel Cancer Center at Jefferson and published online Feb 9. in Clinical Cancer Research.
　　Recurrence occurs in about 25 percent of node-negative patients (pN0), suggesting that occult metastases escaped detection, be it imaging modalities or histopathology.
　　To better predict recurrence and accurately stage these patients, Terry Hyslop, Ph.D. and Scott A. Waldman, M.D., Ph.D. of the Department of Pharmacology and Experimental Therapeutics of Thomas Jefferson University and the Kimmel Cancer Center at Jefferson, and colleagues explored a novel molecular approach, using the biomarker GUCY2C for metastatic colorectal cancer cells.
　　Using 291 colorectal cancer patients who were node-negative, the researchers **yzed lymph nodes by histopathology and GUCY2C quantitative qRT-PCR. They were followed for a median of 24 months and categorized as having either low, intermediate or high tumor burdens.